Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCS12852 in Moderate to Severe Gastroparesis
NCT05270460Phase 2Completed
- Sponsor
- Processa Pharmaceuticals, Inc.
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of YH12852 in gastroparesis (3 arms), sponsored by Processa Pharmaceuticals, Inc. Primary endpoints: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate at 28 days, Change in Gastric Emptying Rate From Baseline at 28 days and 2 more. Started Mar 2022; status: completed.
02
Drugs
YH12852
03
Conditions
gastroparesis
Beyond the preview
Go deeper on NCT05270460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270460.